Abstract
Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Current Signal Transduction Therapy
Title: Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Volume: 5 Issue: 3
Author(s): Hiroshi Harada and Masahiro Hiraoka
Affiliation:
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Abstract: Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Export Options
About this article
Cite this article as:
Harada Hiroshi and Hiraoka Masahiro, Hypoxia-Inducible Factor 1 in Tumor Radioresistance, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920229
DOI https://dx.doi.org/10.2174/157436210791920229 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Factors for Node Affectation and Recurrence in Endometrial Cancer
Current Women`s Health Reviews Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Current Topics in Medicinal Chemistry Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview
Mini-Reviews in Medicinal Chemistry Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Suppression of Erosive Arthritis by NF-κB Inhibitors
Current Rheumatology Reviews Inhibiting Glutathione Metabolism in Lung Lining Fluid as a Strategy to Augment Antioxidant Defense
Current Enzyme Inhibition Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Role of Oxygen in Cancer: Looking Beyond Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Coumarins and 1-Azacoumarins as Versatile Biodynamic Agents
Current Medicinal Chemistry Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern β-Amyloid Apoptotic Injury of Microglia
Current Neurovascular Research B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design